What is the current valuation of the US antiandrogens market in 2024?

The overall market valuation was 1518.43 $ Million in 2024. Read More

What is the projected market size for the US antiandrogens market by 2035?

The projected valuation for 2035 is 3236.09 $ Million. Read More

What is the expected CAGR for the US antiandrogens market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 7.12 %. Read More

Which companies are the key players in the US antiandrogens market?

Key players in the market include AstraZeneca, Bayer, Novartis, Pfizer, Merck & Co, Sanofi, Bristol-Myers Squibb, Eli Lilly, and Teva Pharmaceutical Industries. Read More

What are the main segments of the US antiandrogens market by type?

The main segments by type are Steroidal, valued between 600.0 $ Million and 1300.0 $ Million, and Nonsteroidal, valued between 918.43 $ Million and 1936.09 $ Million. Read More

What is the valuation range for the Prostate Cancer segment in the US antiandrogens market?

The Prostate Cancer segment is valued between 600.0 $ Million and 1300.0 $ Million. Read More

How does the distribution channel impact the US antiandrogens market?

Distribution channels include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Retail Pharmacies valued between 600.0 $ Million and 1300.0 $ Million. Read More

What is the valuation range for the Hirsutism segment in the US antiandrogens market?

The Hirsutism segment is valued between 300.0 $ Million and 600.0 $ Million. Read More

What are the growth prospects for the US antiandrogens market in the coming years?

The market appears poised for growth, with a projected valuation increase to 3236.09 $ Million by 2035. Read More

US Antiandrogens Market

Q: What disease indications are covered in the US antiandrogens market?

The market covers disease indications such as Prostate Cancer, Benign Prostatic Hyperplasia, Hirsutism, Hyperandrogenism, and others. Read More

ID: MRFR/HC/18326-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Antiandrogens Market Research Report By Type (Steroidal, Nonsteroidal), By Disease Indication (Prostate Cancer, Benign Prostatic Hyperplasia, Hirsutism, Hyperandrogenism, Others) and By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth & Industry Forecast 2025 To 2035

US Antiandrogens Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.12%

2024 Market Size$ 1,518.43 Million

2025 Market Size$ 1,626.54 Million

2035 Market Size$ 3,236.09 Million

Key Players

AstraZeneca

Bayer

Novartis

Pfizer

Merck & Co

Sanofi

Trends

Rising Demand for Hormonal Treatments
Regulatory Developments and Innovations
Shift Towards Personalized Medicine

Opportunities

Rising Healthcare Expenditure
Growing Awareness of Gender Dysphoria
Advancements in Pharmaceutical Research

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Steroidal
  2. 4.1.2 Nonsteroidal
2. 4.2 Construction, BY Disease Indication (USD Million)
  1. 4.2.1 Prostate Cancer
  2. 4.2.2 Benign Prostatic Hyperplasia
  3. 4.2.3 Hirsutism
  4. 4.2.4 Hyperandrogenism
  5. 4.2.5 Others
3. 4.3 Construction, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AstraZeneca (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DISEASE INDICATION
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CONSTRUCTION
8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
11. 6.11 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
12. 6.12 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 CONSTRUCTION, BY DISEASE INDICATION, 2024 (% SHARE)
14. 6.14 CONSTRUCTION, BY DISEASE INDICATION, 2024 TO 2035 (USD Million)
15. 6.15 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
16. 6.16 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

Steroidal
Nonsteroidal

Construction By Disease Indication (USD Million, 2025-2035)

Prostate Cancer
Benign Prostatic Hyperplasia
Hirsutism
Hyperandrogenism
Others

Construction By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”